AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38435944
Drug: Postoperative hyperamylasemia
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative hyperamylasemia (POH) defined as serum amylase >100 U/L on postoperative day 1 (POD1)
Trial: 38435944
Drug: Blood loss
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood loss >350 mL, pancreatic duct size <3 mm, elevated POD1 serum amylase >100 U/L
Trial: 38435978
Drug: Web-based EMDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based EMDR intervention (up to 12 sessions, delivered twice weekly)
Trial: 38436365
Drug: One-month dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin
Trial: 38436463
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg once a day for 14 days
Trial: 38436463
Drug: Delpazolid 400
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 400 mg twice a day for 14 days
Trial: 38436463
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg twice a day for 14 days
Trial: 38436463
Drug: Delpazolid 1200
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 1200 mg once a day for 14 days
Trial: 38436495
Drug: Intranasal nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal nalmefene (2.7 mg)
Trial: 38436924
Drug: Regular-strength dual-action
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-strength dual-action tablets (RS-DAT) - niraparib 200 mg/AA 1000 mg once daily
Trial: 38436924
Drug: Lower-strength dual-action
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-strength dual-action tablets (LS-DAT) - niraparib 100 mg/AA 500 mg
Trial: 38436924
Drug: Single-agent combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent combination (SAC) - abiraterone acetate alone
Trial: 38436947
Drug: Silver Diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride (SDF) 38% concentration solution
Trial: 38436947
Drug: Sealants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants with Atraumatic Restorative Treatment (ART)
Trial: 38436998
Drug: Batoclimab (680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab (680 mg, subcutaneous injections, 6 weekly doses)
Trial: 38436998
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, 6 weekly doses)
Trial: 38437725
Drug: CD19-CD28 in
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CD28 in combination with glofitamab
Trial: 38437725
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of glofitamab with CD19-CD28 and CD19-4-1BBL
Trial: 38437868
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of aldosterone
Trial: 38438123
Drug: RTS,S full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S full-dose regimen (2 full doses at months 0 and 1)
Trial: 38438123
Drug: RTS,S fractional-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S fractional-dose regimen (one-fifth doses)
Trial: 38438123
Drug: RTS,S full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S full-dose regimen (R012-14-26)
Trial: 38438123
Drug: RTS,S fractional-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S fractional-dose regimen (Fx012-14-26)
Trial: 38438123
Drug: RTS,S fractional-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S fractional-dose regimen (Fx017-20-32)
Trial: 38438427
Drug: PTX-COVID19-B vaccine
RxNorm normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX-COVID19-B vaccine candidate (40 μg, two doses administered 28 days apart)
Trial: 38438427
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (30 μg, two doses administered 21 days apart)
Trial: 38438427
Drug: PTX-COVID19-B vaccine
RxNorm normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX-COVID19-B vaccine candidate
Trial: 38438681
Drug: 10.5 mg
RxNorm normalized name: pectin 10.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 mg bupivacaine
Trial: 38438681
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg bupivacaine
Trial: 38438681
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg bupivacaine
Trial: 38438681
Drug: 9.75 mg
RxNorm normalized name: sulfur 9.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.75 mg bupivacaine
Trial: 38438923
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg roflumilast
Trial: 38438923
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg roflumilast
Trial: 38439027
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 0.1~1.0 μg/kg/h for 24 h
Trial: 38439092
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy Enhanced (CBT-E)
Trial: 38440130
Drug: OC-01 (varenicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline solution) nasal spray 0.6 mg/mL twice daily (BID)
Trial: 38440130
Drug: OC-01 (varenicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline solution) nasal spray 0.6 mg/mL BID
Trial: 38440130
Drug: Vehicle nasal
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle nasal spray
Trial: 38440179
Drug: Houtou Jianweiling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Houtou Jianweiling tablet
Trial: 38440302
Drug: Super-bioavailability itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Super-bioavailability itraconazole (SUBA-itra)
Trial: 38440406
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) intervention
Trial: 38441576
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab Vedotin (EV) 1.25 mg/kg plus Pembrolizumab 200 mg
Trial: 38441657
Drug: Laparoscopic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic and open surgery for rectal cancer (part of COLOR II trial)
Trial: 38441850
Drug: AbGn-107 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbGn-107 at 1.0 mg/kg every 2 weeks (Q2W)
Trial: 38441854
Drug: 12 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg/day cannabidiol (Epidyolex)
Trial: 38441919
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 2.5 mg + 100 mg placebo
Trial: 38441919
Drug: Modafinil 100
RxNorm normalized name: modafinil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 100 mg + 2.5 mg placebo
Trial: 38441919
Drug: Placebo 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2.5 mg + 100 mg placebo
Trial: 38441919
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (combined with all interventions)
Trial: 38442717
Drug: High-dose rivaroxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rivaroxaban regimen (HDRR, 20/15 mg)
Trial: 38442717
Drug: Low-dose rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rivaroxaban regimen (LDRR, 15/10 mg)
Trial: 38443077
Drug: Survey measuring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey measuring the impact of the cardiac condition on specific life domains (e.g., daily activities, social and family relationships, hobbies, sexual life)
Trial: 38443081
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus daily mobile phone text messages with instructions for outdoor walking and functional leg exercises.
Trial: 38443333
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg orally, twice daily), Bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once every 3 weeks), Durvalumab (1.12 g intravenously, once every 3 weeks)
Trial: 38443354
Drug: Antidepressant monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant monotherapy for 8 weeks
Trial: 38443879
Drug: 2.9 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.9 mm Narrow Diameter Implants (Ti-Zr alloy)
Trial: 38443879
Drug: 3.3 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mm Control Group Implants
Trial: 38443957
Drug: Self-administered at-home
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered at-home lung ultrasound (SAAH-LUS) with remote teleguidance
Trial: 38443989
Drug: Fluoridated bottled
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated bottled water (0.7 mg/L F)
Trial: 38444034
Drug: MTX combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX combined with TNF-α blocker certolizumab pegol (arm CZP)
Trial: 38444034
Drug: MTX combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX combined with IL-6R blocker tocilizumab (arm TCZ)
Trial: 38444064
Drug: Oral probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotics (5 billion colony-forming units each)
Trial: 38444312
Drug: Hybrid-closed loop
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid-closed loop (HCL) therapy from diagnosis of T1D
Trial: 38444429
Drug: CD19-CAR-DNT cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 1 (DL1)
Trial: 38444429
Drug: CD19-CAR-DNT cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 3 (DL3)
Trial: 38444429
Drug: CD19-CAR-DNT cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 4 (DL4)
Trial: 38444519
Drug: Once-daily prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily prolonged-release tacrolimus (Envarsus) for 4 weeks
Trial: 38444861
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell (DC) vaccination combined with carboplatin/paclitaxel chemotherapy
Trial: 38444861
Drug: Carboplatin/paclitaxel chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/paclitaxel chemotherapy
Trial: 38445317
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 8 mg (Group 2)
Trial: 38445382
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) 24 International Units prior to each session of psychotherapy
Trial: 38445541
Drug: Mitiperstat 5
RxNorm normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiperstat 5 mg once daily
Trial: 38445651
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg low-dose melatonin administered 3 hours before the measured DLMO (measured DLMO group, n = 20)
Trial: 38445651
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg low-dose melatonin administered 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20)
Trial: 38445950
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care strategy of guideline-directed medical therapy up-titration
Trial: 38445964
Drug: Once-weekly dordaviprone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly dordaviprone
Trial: 38445964
Drug: Twice-weekly dordaviprone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly dordaviprone
Trial: 38446309
Drug: 90-g transplant
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90-g transplant administered once to the colon (LI)
Trial: 38446309
Drug: 90-g transplant
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90-g transplant administered once to the duodenum (SI)
Trial: 38446309
Drug: 90-g transplant
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90-g transplant administered twice to the distal duodenum (repeated SI)
Trial: 38446336
Drug: ICS-containing treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS-containing treatments
Trial: 38446336
Drug: Non-ICS containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ICS containing treatments
Trial: 38446341
Drug: Cenobamate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (mean dose 262.5 mg/day)
Trial: 38446388
Drug: HEC122505 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC122505 single ascending dose (5, 20, 50, 100, 200, 300, or 400 mg)
Trial: 38446388
Drug: HEC122505 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC122505 multiple ascending dose (20, 50, or 100 mg once daily)
Trial: 38446388
Drug: HEC122505 food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC122505 food effect (100 mg single dose after a high-fat, high-calorie meal)
Trial: 38446482
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (coronary angiography and revascularization if feasible, n=84)
Trial: 38446482
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (medical treatment with coronary angiography only if recurrent ischemia, n=83)
Trial: 38446675
Drug: Chemotherapy (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (gemcitabine and cisplatin or carboplatin)
Trial: 38446860
Drug: In Vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Vivo treatment
Trial: 38447095
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg oral nicotine pouches (ONP) for 8 weeks
Trial: 38447095
Drug: Assessment-only control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment-only control (CC)
Trial: 38447497
Drug: Aquatic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic Therapy (AT)
Trial: 38447497
Drug: Land-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-Based Therapy (LBT)
Trial: 38448064
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment with telemonitoring, home visits by a CPAP technician or nurse at CPAP initiation, followed up for 6 months.
Trial: 38448965
Drug: Corneal crosslinking
RxNorm normalized name: hyaluronic acid, crosslinked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal crosslinking (CXL) treatment before transplantation, with possible repeat if insufficient reduction of corneal neovascularization is observed.
Trial: 38448965
Drug: Corneal crosslinking
RxNorm normalized name: hyaluronic acid, crosslinked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal crosslinking (CXL) treatment with additional fine needle diathermy on the day of transplantation.
Trial: 38449377
Drug: Pembrolizumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle plus SBRT delivered in 1-5 fractions starting on C1D15-28.
Trial: 38449377
Drug: SBRT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT in addition to current therapy for patients who have started an immune checkpoint inhibitor within 60 days.
Trial: 38449767
Drug: Blood levels
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood levels of prescribed drugs
Trial: 38449916
Drug: Anti-PD-1 monoclonal
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 monoclonal antibody infusions
Trial: 38449910
Drug: Adaptations to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptations to the intervention (e.g., drop-in, open group format)
Trial: 38450236
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day elemental Zn
Trial: 38450236
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day elemental Zn
Trial: 38450375
Drug: LDE-paclitaxel (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE-paclitaxel (IV infusion, paclitaxel dose: 175 mg/m2)
Trial: 38450513
Drug: Mitapivat therapy
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitapivat therapy
Trial: 38450551
Drug: Aripiprazole 30
RxNorm normalized name: aripiprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 30 mg tablet orally 3 hours before surgery
Trial: 38450551
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 3 hours before surgery
Trial: 38451273
Drug: Tiragolumab 600
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab 600 mg plus Atezolizumab 1200 mg intravenous every 3 weeks
Trial: 38451491
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) to a dose of 50 Gy in 5 fractions every other day.
Trial: 38451509
Drug: Water-free cyclosporine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-free cyclosporine ophthalmic solution, 0.1% (1 eye drop in each eye twice daily)
Trial: 38451509
Drug: Vehicle (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (1 eye drop in each eye twice daily)
Trial: 38451509
Drug: Water-free cyclosporine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-free cyclosporine ophthalmic solution, 0.1%
Trial: 38451604
Drug: Lacosamide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (initial dose 50 mg orally twice a day, increasing to a maximum of 400 mg/day for 7 days)
Trial: 38451604
Drug: Lacosamide +
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide + Opioid therapy
Trial: 38452035
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg orally twice daily
Trial: 38452059
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg daily with Sildenafil 100 mg daily
Trial: 38452197
Drug: Fitusiran prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran prophylaxis (once-monthly 80 mg for 7 months)
Trial: 38452283
Drug: β3-AR agonist
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β3-AR agonist mirabegron (300 mg/day) for 6 months
Trial: 38452779
Drug: Tafenoquine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 300 mg (single dose)